Atossa Therapeutics (Germany) Performance
| YAG2 Stock | EUR 1.15 0.04 3.60% |
The firm shows a Beta (market volatility) of 0.17, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Atossa Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Atossa Therapeutics is expected to be smaller as well. At this point, Atossa Therapeutics has a negative expected return of -0.0048%. Please make sure to confirm Atossa Therapeutics' maximum drawdown, skewness, daily balance of power, as well as the relationship between the potential upside and kurtosis , to decide if Atossa Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Atossa Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable technical and fundamental indicators, Atossa Therapeutics is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 39.7 M | |
| Total Cashflows From Investing Activities | -9000.00 |
Atossa |
Atossa Therapeutics Relative Risk vs. Return Landscape
If you would invest 119.00 in Atossa Therapeutics on August 28, 2024 and sell it today you would lose (4.00) from holding Atossa Therapeutics or give up 3.36% of portfolio value over 90 days. Atossa Therapeutics is producing return of less than zero assuming 3.1463% volatility of returns over the 90 days investment horizon. Simply put, 28% of all stocks have less volatile historical return distribution than Atossa Therapeutics, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Atossa Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Atossa Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Atossa Therapeutics, and traders can use it to determine the average amount a Atossa Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0015
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | YAG2 |
Estimated Market Risk
| 3.15 actual daily | 28 72% of assets are more volatile |
Expected Return
| 0.0 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Atossa Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Atossa Therapeutics by adding Atossa Therapeutics to a well-diversified portfolio.
Atossa Therapeutics Fundamentals Growth
Atossa Stock prices reflect investors' perceptions of the future prospects and financial health of Atossa Therapeutics, and Atossa Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Atossa Stock performance.
| Return On Equity | -0.18 | |||
| Return On Asset | -0.11 | |||
| Current Valuation | (59.13 M) | |||
| Shares Outstanding | 126.62 M | |||
| Price To Book | 0.64 X | |||
| EBITDA | (20.5 M) | |||
| Cash And Equivalents | 131.49 M | |||
| Cash Per Share | 1.04 X | |||
| Total Debt | 1.22 K | |||
| Book Value Per Share | 0.97 X | |||
| Cash Flow From Operations | (16.47 M) | |||
| Earnings Per Share | (0.17) X | |||
| Total Asset | 141.26 M | |||
About Atossa Therapeutics Performance
By analyzing Atossa Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Atossa Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Atossa Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Atossa Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington. ATOSSA THERAPEU operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 6 people.Things to note about Atossa Therapeutics performance evaluation
Checking the ongoing alerts about Atossa Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Atossa Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Atossa Therapeutics generated a negative expected return over the last 90 days | |
| Atossa Therapeutics may become a speculative penny stock | |
| Atossa Therapeutics has high historical volatility and very poor performance | |
| Atossa Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (20.61 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Atossa Therapeutics has accumulated about 131.49 M in cash with (16.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.04. |
- Analyzing Atossa Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Atossa Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Atossa Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Atossa Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Atossa Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Atossa Therapeutics' stock. These opinions can provide insight into Atossa Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Atossa Stock analysis
When running Atossa Therapeutics' price analysis, check to measure Atossa Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atossa Therapeutics is operating at the current time. Most of Atossa Therapeutics' value examination focuses on studying past and present price action to predict the probability of Atossa Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atossa Therapeutics' price. Additionally, you may evaluate how the addition of Atossa Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |